Close
Digital Health & Ai Innovation summit 2026
APE 2026

CMS liberates implantable cardioverter-defibrillator (ICD); final coverage policy

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Maimonides Health Merger with NYC Health...

Maimonides Health, which is Brooklyn, New York-based, is going ahead...

Nada to Capture Clinical Notes from...

PureHealth has commenced the pilot phase of Nada, which...

Advanced UV Adhesives for Medical Device...

Hoenle Adhesives is going ahead and bringing to the...

The NCD will continue to govern patient criteria and covered indications for CMS reimbursement of ICD implantation.

The new NCD requires a shared decision-making encounter using a tool, updates clinical indications, and incorporates several exemptions for waiting periods. In a notable change from the draft NCD released last November, the shared decision-making encounter does not need to be completed by an “independent” clinician.

The NCD also ends the requirement for data collection for evidence development, which sites have satisfied through participation in ACC’s ICD Registry. However, enrollment in the ICD Registry will continue to provide evidence of compliance with CMS reimbursement criteria.

In response to the draft NCD, the ACC, in collaboration with the Heart Rhythm Society, submitted public comments to CMS, recommending that the policy be updated to reflect current, evidence-based science and guideline recommendations that have changed since the policy was issued – including the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.

“Ongoing collaboration and coordination among CMS, the U.S. Food and Drug Administration, the National Institutes of Health, the Agency for Healthcare Research and Quality, and other federal agencies presents an opportunity to ensure funding and timely completion of well-designed studies to answer outstanding questions,” ACC President Mary Norine Walsh, MD, FACC, and George F. Van Hare, MD, FHRS, FACC, president of the Heart Rhythm Society, wrote in the comment letter. “The Societies support the coverage with evidence development paradigm to expedite earlier access to innovative technologies that are likely to show benefit for the Medicare population where there is incomplete evidence.”

The changes are effective immediately, though contractors must wait for further technical instructions from CMS before updating claims processing software. ACC staff are reviewing the final decision to identify any additional topics of interest to members. More information will be forthcoming in the Advocate newsletter and on ACC.org in the coming weeks.

Latest stories

Related stories

Maimonides Health Merger with NYC Health + Hospitals Soon

Maimonides Health, which is Brooklyn, New York-based, is going ahead...

Nada to Capture Clinical Notes from Medical Conversations

PureHealth has commenced the pilot phase of Nada, which...

Advanced UV Adhesives for Medical Device Assembly Introduced

Hoenle Adhesives is going ahead and bringing to the...

Spinoff from 3M Health Care Acquires Acera Surgical

Solventum went ahead and shared on December 23, 2025,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »